Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Investor Presentation (August 2025)
22 slides from Akari Therapeutics's investor presentation, August 2025
Slide 1: Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads
August 2025 Advancing Antibody Drug Conjugates With Corporate Overview Novel Immuno-Oncology Payloads NASDAQ: AKTX akaritx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc
Slide 3: We Are Akari Therapeutics
WE ARE AKARI THERAPEUTICS Akari Therapeutics is Focused on Innovating Antibody Drug Conjugates as Immuno-Oncology Therapies for Patients to Be Cancer Free 3
Slide 4: Corporate Overview
Corporate Overview Advancing Next-Generation Lead Program AKTX-101 (TROP2 PH1 ADC) Antibody Drug Conjugates - IND/First-in-human regulatory filing in H2 2026 Designed with Novel Immuno- - Initial Focus: bladder, gastric, and lung cancer Oncology Payloads - Strong preclinical data showing potent tumo
Slide 5: Akari Is Advancing PH1 Payload In Multiple ADC Programs
Akari Is Advancing PH1 Payload In Multiple ADC Programs PH1 payload is the cornerstone of building an ADC pipeline against wide range of tumors ADC Programs Indication Discovery Preclinical Clinical Highlights (All PH1 Payload based) Bladder, • Ready for IND enabling studies AKTX-101 Gastric, and su
Slide 6: Senior Leadership Team Brings Deep Oncology/Biotech Experience
Senior Leadership Team Brings Deep Oncology/Biotech Experience Abizer Gaslightwala, Torsten Hombeck, PhD Satyajit Mitra, PhD Mark F. Kubik MS, MBA Chief Financial Officer Executive Director, Head of Business President, Head of Oncology Development – Oncology Chief Executive Officer Seasoned executiv
Slide 7: ADCs Continue To Drive Cancer Therapeutic Class With Several Blockbuster Products
ADCs Continue To Drive Cancer Therapeutic Class With Several Blockbuster Products > $1B sales Global ADC Market Projected to Surpass >$34B by 2032 1 However, Current ADC Landscape Continues to Focus on Limited Payloads With Known Limitations 2024 Sales from Approved ADCs However, Payload Innovation
Slide 8: Efficacy Outcomes Across Current ADCs Highlight The Need for New ADCs
Efficacy Outcomes Across A Range of Current ADCs Highlight The Need for New ADCs To Improve Response Rates and Durability ADC Therapies as Monotherapies (Trop2, Nectin4, Folate Alpha, Tissue Factor) Topo-1 Inhibitors Microtubule Inhibitors ≤50% ~50% ~50% ≤50% Do Not Do Not Respond Respond Respond Re
Slide 9: Akari Is Advancing A New Class of ADCs: Immuno-Oncology ADCs Centered Around PH1 Payload
Akari Is Advancing A New Class of ADCs: Immuno-Oncology ADCs Centered Around PH1 Payload Novel PH1 Payload is a Spliceosome Modulator That Has A Unique Efficacy and Safety Profile to Address Unmet Needs of Current ADCs Potential Advantages of ADCs with PH1 Payload Kills Cancer Cells While Synergy Wi
Slide 10: PH1 Payload Uses a 1-2 Punch To Kill Cancer Cells
PH1 payload Uses a 1-2 Punch To Kill Cancer Cells: (1) Cytotoxicity (2) Immune Activation To Kill Tumor Cells Beyond Those Targeted by ADC Tumor Microenvironment Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 ADC molecules bind Increased antigenicity in Tumor Epitope spreading primes immune Activated Imm
Slide 11: Lead Program AKTX-101 (TROP2 PH1 ADC)
Lead Program AKTX-101 (TROP2 PH1 ADC) Targeting Trop2 Cancers With Spliceosome Modulator Payload After 1st line ADCs IND/FIH Regulatory filing targeting H2 2026 Targeting Significant Unmet Need in Bladder Cancer Post Enfortumab Vedotin (PADCEV®) Large potential opportunities in Gastric and Lung Canc
Slide 12: AKTX-101 Demonstrates Activity In Difficult Bladder Cancer Model
AKTX-101 Demonstrates Compelling Activity In Difficult Bladder Cancer Model Both As Single Agent and Synergistically with Checkpoint Inhibitors Superior Anti-Tumor Activity Superior Overall Survival In Combination With IO Combination With IO hTrop2 Bladder Kaplan Meier 3000 Vehicle 100 Vehicle Tumor
Slide 13: AKTX-101 Has Superior Activity Compared To Marketed ADC Trodelvy
We believe AKTX-101 Has Superior Activity Compared To A Marketed ADC, Trodelvy®, Based on Results from Preclinical Models Higher Rate of Tumor Regression Compared to Trodelvy®, Even with Lower Dose and Drug/Antibody ratio (DAR) 10mg/kg 3mg/kg Method NCI-N87 cell xenograft model Tumor Volume (mm3) Mi
Slide 14: PH1 Payload Drives Tumor Regression and Creates Immunological Memory
PH1 Payload Drives Cancer Tumor Regression and Creates Immunological Memory That Prevents Tumor Recurrence Part 1: Potent Activity of PH1 ADC As Single Agent Part 2: PH1 Payload Induces Tumor-Specific and With Checkpoint Inhibitor Immunological Memory Against Cancer Cells ADC Treatment and Survival
Slide 15: PH1 Payload Designed to Overcome Traditional Resistance Mechanisms
120 PH1 Payload Designed to Overcome 100 % Live Cells 80 Traditional Resistance Mechanisms 60 40 MES-SA MES-SA/MX2 PH1 MES-SA/MX2 + Experienced by Currently Approved 20 0 Elacridar or in Development ADC Payloads 0.0001 0.01 1 100 Concentration [nM] 10000 PH1 potency unaffected by overexpression of M
Slide 16: Trop2 PH1 ADC Has Favorable Safety Profile in Non-Human Primate Study
Trop2 PH1 ADC has Demonstrated Favorable Safety Profile in Non-Human Primate Study No toxicities such as interstitial lung disease, neutropenia, mucosal inflammation or neuropathies were observed Tolerated in NHP at doses well above Mitigatable side-effects that reset to efficacious dose baseline wi
Slide 17: AKTX-101 Path To IND/FIH Filing Based on Target Key Milestones
AKTX-101 Path To IND/FIH Registrational Filing Based on Target Key Milestones* 2025 2026 4Q H1 H2 Topline Results of New Target Completion Expected Final GLP Toxicology Preclinical Studies of Initial GMP /Nonclinical Package (Lung) Manufacturing Batches Finalize FIH Phase 1 Study Protocol Expect to
Slide 18: Second Lead Program AKTX-102 (undisclosed target)
Second Lead Program AKTX-102 (undisclosed target) Potential Best-in-Class ADC with novel antibody design/target linked to PH1 payload Expected to disclose target and more details by end of 2025 Advancing rapidly into Preclinical Development Expanding PH1 payload platform into high-value oncology ind
Slide 19: Early Stage ADCs Continue To See Strong Interest and Deal Flow
Early Stage ADC’s Continue To See Strong Interest and Deal Flow Licensee Licensor Phase Asset Target Date Deal Type Upfront Payment Total Deal Highlights $130M upfront + potential $70M in near-term milestones; Phase 2 2 ADCs CLDN18.2 5/2025 Licensing $130M $1.34B in development, regulatory and comme
Slide 20: Target Key Value Drivers - 2025
Target Key Value Drivers - 2025 2025 2026 4Q H1 H2 Topline Results of New Target Completion Expected Final GLP Toxicology Preclinical Studies AKTX-101 of Initial GMP / Nonclinical Package (Lung) Manufacturing Batches Finalize FIH Phase 1 Study Protocol AKTX-102 Expected to disclose target and more d
Slide 21: Investment Summary
Investment Summary Antibody Drug Conjugates Designed with Novel Immuno- Oncology Payload, PH1 (spliceosome modulator) Filling significant gap in ADC payload innovation • >90% use DNA damaging agents (topo-1 inhibitors, others) or microtubule inhibitors AKTX-101: Lead TROP2 ADC has clear timeline and
Slide 22: Thank You!
Thank You! Investor Relations Advancing Antibody Drug Conjugates With JTC Team aktx@jtcir.com Novel Immuno-Oncology Payloads (908) 824-0775
Akari Therapeutics — Investor Presentation (August 2025) on 6ix